Remote Australian town seeking doctor offers $400,000 salary and free rent
WELLINGTON, New Zealand — A remote Australian town that will soon lose its only doctor is offering a salary of up to $428,000, plus free rent and a car, to attract candidates.
The remote Queensland town of Julia Creek, population 500, is offering about double the salary a family physician would earn in the state's capital, Brisbane. The catch is that Brisbane is a 17-hour drive away. The closest major city, Townsville, is a seven-hour drive.
Prospective applicants must embrace searing heat and tropical insects too.
But the town's outgoing physician, Adam Louws, says his replacement will also find a quieter pace of life and the chance to learn skills they've never used before.
Louws was recruited from Brisbane in 2022, when Julia Creek drew national headlines for offering a salary of more than $300,000.
'My mother-in-law sent me a link to this news article saying, 'the half a million dollar [in Australian currency] job that no one wants,'' Louws said. 'My first thought when I saw it and I looked at it was, 'Where's Julia Creek?''
Julia Creek is a sweeping, romantic slice of the Australian Outback with wide-open spaces and orange sunsets. Kids play sports and ride horses. But it's remote — high school means boarding school in the city and the nearest hospital is a nearly three-hour drive away.
Before Louws arrived in 2022, the town hadn't had a permanent doctor for 15 years, with a roster of visiting physicians dropping in for short stays. It's a problem that has vexed rural towns in Australia and around the world for decades.
Australia has a shortfall of 2,500 general practitioners across the country, according to a 2024 government report, with the shortage worst in rural areas and expected to grow. Attracting doctors to rural Australia is made harder by the eye-watering distances between the most remote settlements; the vast country is one of the world's least densely populated.
In neighboring New Zealand — where 5 million people live in a country the size of the United Kingdom — distances between far-flung towns have worsened health disparities. In the United States, 65% of rural areas had a shortage of primary care physicians in 2023, official figures showed.
Janene Fegan, the mayor of McKinlay Shire — which includes Julia Creek — knew the town needed a good sales pitch. Fegan was involved in the local health service's campaign that recruited Louws and offered to promote the town again when the job was advertised in March.
'We actually have a very, very good lifestyle and a very safe lifestyle,' she said. 'Yes, there is distance to travel at times, but how many people do you hear now wanting to escape from that and go off-grid?'
The town was not, she added, literally off the grid: Julia Creek has electricity and broadband internet.
'You don't have to stay forever,' Fegan said. 'Just give it a shot.'
When the job was advertised in 2022, some healthcare analysts said the bolstered salary still wasn't enough to compensate for a solo doctor's workload.
But Louws, the departing doctor, said working solo prompted him to learn medical skills that he would have sent patients 'two minutes down the road' for another practitioner to perform when he lived in the city. He also fulfilled a childhood dream of learning to milk dairy cows.
'The money is plenty. It is,' Louws said. 'One of the things that I think people don't necessarily consider enough about this job is the other things that this town has to offer.'
Louws applied for the job three days after first hearing about Julia Creek, following study on Wikipedia. Soon, he and his wife and four children were packing to move.
When he'd been in the job six months, Louws said, he knew 'nine out of 10' people in the town by name. 'It feels kind of like stepping back in time about 60-odd years,' he said. 'Everyone knows everyone.'
At the end of his two-year contract in Julia Creek, however, the distance from his extended family had taken a toll and he plans to return to his practice in the city. Louws departs in May; applications for his post close Sunday.
He's sorry to be leaving the 'incredible' town.
'It feels a lot closer,' the doctor said. 'You get to really make a difference.'
Graham-McLay writes for the Associated Press.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Australian jailed in Iraq conditionally released after four years
An Australian man has been conditionally released from prison in Iraq, after four years of what the UN has called arbitrary detention. Robert Pether, a mechanical engineer, was jailed in 2021 on fraud charges amid a contract dispute between the consulting firm he worked for and the Central Bank of Iraq. The UN has said the 50-year-old's detention and treatment was illegal, and an international court has ruled his employer is not responsible for the business disagreement. Iraqi officials are yet to provide an explanation for the decision, Mr Pether's wife Desree told the BBC - noting her "extremely sick" husband is still banned from leaving the country despite needing urgent medical care. The family feels numb with shock, said Mrs Pether, who has been tirelessly lobbying for this moment. "It's the first time in over four years that we've taken one step in the right direction." "There's a tiny glimmer of hope, but there's another mountain still to go over." "He really needs to be home and in hospital." Simon Harris, the tánaiste (deputy prime minister) of Ireland - where the Pether family lives - said in a statement to media that Iraq's Foreign Minister had called him to confirm the "welcome news". "[This] has been a long and distressing saga for Robert's wife, three children and his wider family and friends," Harris said. "I welcomed this as a first step to his being allowed to return to his family in Roscommon." He added that he remained concerned about Mr Pether's health and any outstanding charges against him - which are unclear. The BBC has contacted the Australian government for comment. Mr Pether worked in the Middle East for almost a decade before taking on a huge rebuild of the Central Bank of Iraq's Baghdad headquarters in 2015. He was arrested alongside his CME Consulting colleague, Egyptian Khalid Radwan, after the bank accused the men of stealing money from the project. After being held without charge for almost six months, and then subjected to a speedy trial, the two were each given a five-year jail sentence and a joint fine of $12m (A$18.4m, £8.8m). However, a 2022 report from the UN determined that the case contravened international law, and that Mr Pether and Mr Khalid had been subjected to "abusive and coercive" interrogations. Iraq's government has previously denied allegations of ill treatment. In 2023, the International Chamber of Commerce's (ICC) Court of Arbitration ruled that Iraq's central bank was at fault in the dispute with CME, and ordered it to pay $13m to the company. Mrs Pether said she spoke to her husband after his release on Thursday night. "He's on a bit of a high tonight, but I think he'll probably come crashing down tomorrow." He looked sick and weak, she said, noting that he can't keep food down and hasn't eaten properly in months. There are also worries he has a potential skin cancer relapse, she added. "He's unrecognisable. If he got on a plane now and they were checking his passport, they would not know it was the same person." She said efforts are now turning to have Mr Pether's travel ban lifted, but in the meantime the family has turned to crowdfunding to try to get him private hospital care in Baghdad. "Enough is enough," Mrs Pether said. "He needs to come home." Australian jailed in Iraq reaches grim milestone 'My husband faces death in an Iraq jail'


New York Times
14 hours ago
- New York Times
MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.
The technology that powered Covid vaccines may also lead scientists to a cure for H.I.V. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary, and so far, has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting H.I.V. 'mRNA is just this miraculous — I really do think miraculous — tool to deliver things that you want into places that were not possible before,' said Dr. Sharon Lewin, director of the Cumming Global Center for Pandemic Therapeutics in Melbourne, who led the study. Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. Want all of The Times? Subscribe.
Yahoo
a day ago
- Yahoo
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Media: Michelle Lefler | VP, Communications & PR | media@ For Investors: ICR, Inc. | aurora@ Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. Sign in to access your portfolio